. After elution from the column and derivatization, gas chromatography-mass spectrometry results showed that the target compound eluted from the SPE cartridge prior to its deuterated form. This elution separation effect was greater for 3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine (MAMP) than for the other drugs studied. When the drugs were eluted in 0.5 mL increments from a 50 mg sorbent bed, no drug appeared in the first fraction. The drug to internal standard ratios (expected value 1.00) for subsequent fractions collected were 1.30, 1.07, and 0. 
Introduction
Amphetamine (AMP) and methamphetamine (MAMP) are stimulants of the central nervous system (1) . Their designer methylenedioxy analogues, 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxymethamphetamine (MDMA), and 3,4-methylenedioxyethamphetamine (MDEA) are Schedule I drugs that cause the user to experience euphoria, sociability, and a sense of general well-being (2, 3) . Because of their addictive nature and adverse health effects, illegal use of these drugs by members of the United States Armed Forces is detrimental to military readiness, due to compromised service member health and mission performance.
An effective approach to deter the use of illicit drugs, including AMP, MAMP, and their designer methylenedioxy analogues in the workforce is to monitor employees and military personnel through random drug testing (4, 5) . Forensic analysis of urine specimens for these amphetamines by the Department of Defense (DoD) (6, 7) or Department of Health and Human Services guidelines (8) requires initial immunoassay test(s) followed by confirmation and quantification by gas chromatography-mass spectrometry (GC-MS).
Accurate quantification of AMP, MAMP, MDA, MDMA, MDEA, and other drugs of abuse has been achieved by the use of deuterated internal standards that have chemical and physical properties that are almost identical to that of the parent drug. The only difference between the drug and its deuterated internal standard is that one or more hydrogen atoms has/have been substituted with deuterium. MS is ideally suited for identification and quantification because the drug and internal standard can easily be distinguished from one another by the increased mass resulting from the substitution of deuterium for one or more hydrogens.
Although the use of deuterated internal standards is the method of choice in most forensic urine testing laboratories, some limitations have been reported. MS fragmentation can include [M -H n ] processes that generate a series of "cluster ions", where n is the number of hydrogens involved in the process. Deuterated internal standards can also include [M -D n ] processes that are likely to generate ions interfering with the intensities of some of the ions attributed to unlabeled drug (9, 10) . Additionally, ionization efficiencies of a drug and its deuterated analogue may differ because of differences in concentrations and retention times. These effects would not be expected with other isotopically labeled analogues such as 13 C internal standards (10) .
In order to perform quantitative analysis by GC-MS or other analytical methods, the drug and internal standard were ex-tracted from a sample matrix using procedures such as liquidliquid and solid-phase extraction (SPE) (11, 12) . Various studies have reported the success of SPE applied to the analysis of many drugs, including AMP, MAMP, and their methylenedioxy derivatives (13) (14) (15) (16) (17) (18) (19) (20) .
There are several commercially available brands of SPE columns with different resin beds that have been used for extraction of amphetamines (13, 14, 21) . Selecting the appropriate SPE column depends upon the volume of the specimen, the specimen matrix, the sensitivity of the analytical method and the characteristics of the analyte. The Cerex ® Polycrom™ CLIN II SPE columns evaluated in this study are mixed mode with a hydrophobic highly cross-linked divinylbenzene (DVB) polymer and strong cation exchanger in the form of bound sulfonic (SO 3 -) groups. This column does not need pre-conditioning, and the small 10-µm particle size provides sufficient surface area for drug binding in a 35-or 50-mg resin bed.
The purpose of the current study was to conduct comparative elution analysis of AMP, MAMP, MDA, MDMA, and MDEA and their respective internal standards using strong cation-exchange SPE Cerex PolyCrom CLIN II columns with a 50-mg resin bed. Experiments were devised to challenge the assumption that amphetamine-like drugs and their internal standards are eluted equally from SPE columns. Results from this study can help in determining the appropriate elution volume and extraction procedures for eluting drugs of abuse from SPE columns. It was not the intention of this study to provide a comprehensive comparison of SPE columns from alternate vendors, but rather to assess the general elution characteristics of amphetaminelike drugs on Cerex Polycrom CLIN II columns.
Experimental Procedures Materials
Methanol, ethyl acetate, hydrochloric acid, sodium periodate, sodium hydroxide, ammonium hydroxide, and dibasic potassium phosphate were all ACS grade purchased from Fisher Scientific (Fairlawn, NJ). The derivatizing reagents, heptafluorobutyric anhydride (HFBA) and R-(-)-α-methoxy-α-(trifluoromethyl) phenylacetyl chloride (R-MTPA), were obtained from Sigma Aldrich-Fluka (St. IN) . Cerex Polycrom CLIN II with 50 mg (6-mL capacity) of sorbent were purchased from SPEware (Baldwin Park, CA).
Extraction
All extraction steps were done using Speedisk ® 48 positivepressure extraction manifolds (SPEware, San Pedro, CA) and polymer-based cation exchange/mixed-bed extraction columns (Cerex Polycrom CLIN II, 50-mg resin bed), as described by Klette et al. (22) .
Samples were prepared by pipetting 2.0-mL aliquots of standards or controls containing MDA, MDMA, and MDEA into 15-mL glass centrifuge tubes (Kimble Chase, Vineland, NJ). A 100-µL aliquot of internal standard solution containing 0.01 mg/mL each of MDA-d 5 , MDMA-d 5 , and MDEA-d 6 and 0.75 mL of 2.3 M phosphate buffer (pH 9.0) was added to each sample. In a similar manner, 100 µL of internal standard solution containing 0.01 mg/mL each of AMP-d 11 and MAMPd 14 , 1.0 mL of 2.3 M phosphate buffer (pH 9.0), and 3.0 mL of 0.1 M sodium periodate were added to 2.0 mL of urine sample that contained AMP and MAMP. All samples were vortex mixed for 5 s. Specimens that were treated with periodate were capped and incubated for 10 min at room temperature. Periodate oxidation prevents potential interference from overthe-counter medications containing pseudoephedrine and ephedrine which may be present in urine specimens (23) . All specimens were centrifuged at 2000 rpm for 5 min to remove any precipitate. Samples were then poured into 50 mg Cerex Polycrom CLIN II SPE columns and placed onto the Speedisk ® apparatus. A low nitrogen flow of 2-3 standard cubic feet/h (SCFH) was applied to load the columns. Next, 2.0 mL of distilled water was applied to the columns followed by 2.0 mL 0.1M HCl (For MDA, MDM, and MDEA) or 0.1M acetic acid (for AMP and MAMP). Nitrogen gas (2-3 SCFH) was applied after addition of each reagent, and then the columns were dried for 2-3 min at 25 psi. The columns were then washed with 2.0 mL of methanol and 2.0 mL of ethyl acetate. Nitrogen gas (2-3 SCFH) was applied after the addition of each reagent and the columns were dried for 2-3 min at 25 psi. A solution of ethyl acetate/ammonium hydroxide (98:2) or methylene chloride/acetone/triethylamine (80:20:2) was used to elute AMP and MAMP, whereas a solution of ethyl acetate/ methanol/ammonium hydroxide (80:20:2) was used to elute MDA, MDMA, and MDEA. The target compounds were eluted by gravity flow either directly into 1.5-mL capacity autosampler vials (ALS) vials for MDA, MDMA, and MDEA, or into 15.0-mL conical tubes for AMP and MAMP. Fractions with 0.5 mL elution volume were incrementally collected until the drugs had fully eluted from the column. In some cases, a low nitrogen flow of 2-3 SCFH was applied for the collection of the first 0.5 mL fraction. After addition of 0.050 mL of 1% concentrated HCl in methanol to each eluate, the eluates were evaporated to dryness.
Derivatization
MDA, MDMA, and MDEA samples were derivatized by adding 0.035 mL HFBA and 0.100 mL ethyl acetate to the ALS vials that were then capped, mixed and incubated for 10 min at 60-70°C. Samples were removed from the heating block, allowed to cool, and then evaporated to dryness at 50-60°C under a stream of nitrogen. Samples were reconstituted in 100 µL of ethyl acetate for GC-MS analysis. d-AMP and d-MAMP samples were derivatized by adding 20 µL of R-MTPA solution (500 mg R-MTPA in 8.0 mL acetonitrile) and 200 µL chlorobutane/triethylamine (100:7.5) to the 15.0-mL collection glass tubes. Samples were vortex mixed, capped, and incubated in a heating block at 60°C for 30 min, at which time 0.100 mL anhydrous ethanol was added. Samples were vortexed for approximately 15 s, and then reincubated in a heating block for 30 min at 60°C. Tubes were removed and evaporated to dryness at 30°C under a stream of nitrogen. Samples were reconstituted in 200 µL of ethyl acetate prior to transfer to ALS vials for GC-MS analysis.
Analysis
All samples were analyzed by GC-MS under selected ion monitoring (SIM) mode using an Agilent Technologies (Palo Alto, CA) 6890N GC and a 5973N mass selective detector. GC injections were performed with a 7683 automated liquid sampler. Drug to internal standard ratios were calculated directly from the area abundance printed on the chromatograms.
MDA, MDMA, and MDEA method
GC separations were performed using an Agilent J&W (Wilmington, DE) DB-5ms bonded-phase capillary column (15 m × 0.25-mm diameter, 0.25-µm film thickness). The injection port temperature was 245°C. Initial oven temperature was maintained at 150°C for 0.10 min then ramped at 30°C/min to 250°C and held for 1 min. All injections were performed with a split ratio of 12:1 using helium as a carrier gas and a column flow rate of 0.6 mL/min. The transfer line temperature was 295°C.
AMP and MAMP method
GC separations were performed using an Ultra 1 (methyl siloxane bonded-phase) capillary column (25 m × 0.200-mm, 0.33-µm film thickness). The injection port temperature was 220°C. GC separations were performed under isothermal conditions with an oven temperature of 210°C. Samples were injected under split mode using a split ratio of 10:1 using helium as a carrier gas and a column flow rate of 0.9 mL/min. The transfer line temperature was maintained at 280°C. All quantifications were made using Agilent MSD ChemStation version E.01 software. Analyte concentrations for specimens and controls were determined by single-point calibration at the current DoD cutoff. For d-AMP and d-MAMP, the calibration standard contained 100 ng/mL of each drug. The MDA, MDMA, and MDEA calibration standard contained 500 ng/mL of each drug. Table I shows the ions and ion ratios used for analysis.
Results and Discussion
Because the drug to internal standard ratio is the basis for quantification, recovery of both the analyte of interest and its corresponding deuterium labeled internal standard during the extraction process is critical. Elution profiles show the amount of drug eluting off of the column versus volume. The internal standard and drug should elute from the SPE cartridge at the same time or in the same proportion in order to have consistent recoveries and quantification. Differences in the binding of the drug and internal standard to the column resin have the potential to produce quantification errors if all of the drug and internal standard are not eluted uniformly from the column.
MDA, MDMA, and MDEA
In order to assess the elution profiles during SPE, urine specimens containing 500 ng/mL MDA, MDA-d 5 , MDMA, MDMA-d 5 , MDEA, and MDEA-d 6 ( Figure 1 ) were applied to Cerex Polycrom CLIN II SPE columns with a sorbent bed size of 50 mg and eluted in 0.5-mL increments. Ten 0.5-mL fractions were collected, but over 99% of the drugs were eluted in the first six or seven fractions. Aliquots containing less than 1% of drug are not shown in the figures. After derivatization and analysis by GC-MS, the fraction of drug and internal standard eluted in each aliquot was calculated from the ion abundances of the quantitative ions for the drug and corresponding internal standard (Table I ). The theoretical ratio of drug to internal standard (DI ratio) is 1.00; however, the actual DI ratio may be greater or less than unity because of the actual concentration of the starting material and any experimental error in the procedure. Differences in DI ratios between the collected 0.5-mL fractions indicate non-uniform elution and, therefore, differences in partitioning of the drugs between the column sorbent and the elution solvent.
The DI ratios for MDA/MDA-d 5 , MDMA/MDMA-d 5 , and MDEA/MDEA-d 6 (Figures 2-4 , respectively) were greater than unity for the early fractions and less than unity in the later fractions, indicating that the drug is eluted prior to its deuterated analogue. For example in Figure 2 , a ratio of 1.30 for MDA/MDA-d 5 revealed that the second 0.5-mL fraction contained 57% MDA and 43% of MDA-d 5 . The third 0.5-mL fraction from this column had a ratio of 1.07 corresponding to 52% of MDA and 47% of MDA-d 5 . If elutions were uniform, the DI ratios of these fractions would be unity with each analyte present at 50%. Both analytes were fully eluted with 2.5 mL of elution buffer with a cumulative DI ratio of 1.12. Similarly, MDEA and its internal standard exhibited elution profiles analogous to those of MDA and MDA-d 5 ( Figure 3) . Again, early fractions favor drug elution over internal standard and the cumulative DI ratio after 2.5 mL of elution buffer was 1.16. In contrast, MDMA shows an even more pronounced difference in elution profile from its internal standard than for MDA or MDEA (Figure 4) . The early fractions again contain more drug, and the latter contain more internal standard. Specifically, the successive fractions had DI ratios above and then below unity, corresponding to 62%, 56%, 45%, and 36% MDMA for fractions 2-5, respectively. More elution buffer was required for full elution of analytes with a cumulative DI ratio of 1.07.
The difference in binding affinity between MDMA and the other two designer amphetamines implicates the methyl-and ethyl-groups bound to the amine as significant to such interactions. Because the apparent order of elution does not follow expected trends in increased hydrophobicity imparted by these substituents and proportional interaction with the same phase in the resin (24), the stronger ionic interactions of the basic moiety with the sulfonate groups of the resin must predominate. Alkylation of the amine modulates interactions for methyl and less so for ethyl or no alkyl group for MDMA, MDEA, and MDA. This follows the expected trend where additional alkyl groups, in general, increase basicity of amines through inductive effects, yet steric effects prevent such trends from increasing in parallel with increases in the number of substituents on the amine or their relative sizes. Consequently, the observed affinities are most likely due to perturbations in basicity of the amines, where the inductive effect from the amino methyl group causes MDMA to be more basic than MDA, but the binding of MDEA is reduced compared to MDMA due to a steric interaction of the larger amino ethyl group. For all of the drugs, deuteration caused higher affinity for the packing material as discussed later, but the binding of MDMA-d 5 was additionally increased because of the proximity of the deuteriums to the nitrogen.
Amphetamine and methamphetamine
Urine specimens containing d-AMP, AMP-d 11 , d-MAMP, and MAMP-d 14 were applied to 50-mg Cerex Polycrom CLIN II SPE columns and eluted with 0.5-mL aliquots of ethylacetate/ammonium hydroxide (98:2). After derivatization and analysis by GC-MS, the fraction of drug and internal standard eluted in each aliquot was calculated from the ion abundances of the quantitative ions for the drug and corresponding internal standard (Table I ). The theoretical DI ratio was 0.40 (100 ng/mL drug to 250 ng/mL internal standard) with any deviation indicating non-uniform elution and, therefore, differences in binding affinities to the column sorbent.
As with the designer amphetamines, the drugs and internal standards were present in different proportions in successive fractions and the methyl analogue eluted later than nonmethylated compounds, presumably due to the previously discussed differences in the affinity of each drug to the column packing material ( Figure 5 When the polarity of the elution solvent was changed, there were still differences in the elution profiles between the drug and its corresponding internal standard. 
Degree and position of deuterium substitution
Molecules where hydrogen has been replaced by deuterium have been shown to have slightly different properties compared to the non-deuterated molecules (25) . The C-H bond has a higher vibrational frequency, a longer bond length and is weaker compared to the C-D bond. The shorter C-D bond length results in a more compact electron distribution, a decrease in electronic polarizability and a slightly increased ability of the C-D bond to donate electron density by an inductive effect. Steric effects are expected to be less with deuterated compounds because of the more compact size imparted by the shorter C-D bonds compared to C-H bonds (26) . These properties can cause small but measurable differences in binding affinities of the drug and its deuterated internal standard. Cody et al. (11) reported gas-phase separation between an analyte and its deuterated analogue using HP-1, HP-5, and DB-17 GC columns, and concluded that the observed separations were correlated to the amount of deuteration
To investigate the effect of the number of deuterium atoms on the binding of AMP and MAMP to Cerex Polycrom CLIN II SPE columns, the binding of two other deuterated drugs, AMPd 6 These data indicate that analyte affinity for the column resin increases with increasing deuteration and more so for methamphetamine.
Although the difference of nine deuteriums between d-MAMP-d 5 14 include the five deuterium substitutions on the phenyl ring, one deuterium on the beta carbon, and three deuteriums on the methyl group attached to the alpha carbon. Taken together, these data indicate that deuteriums either enhance the basicity of the proximal amine through increased induction from the higher electron density imparted by the shorter C-D bond length, or enhance hydrophobic affinity of the propyl moiety, with aryl interactions being less significant. That the former enhancement to basicity is more significant is supported by the greater discrimination between d-AMP and d-MAMP, and MDA and MDMA, due to induction from the methyl group, as discussed previously.
Several studies (11, 25, (27) (28) (29) have shown that, in general, deuteration of hydrocarbons will produce a more polar molecule, but if heteroatoms such as N, O, or S are present, deuteration may either increase or decrease the hydrophobicity depending upon the position of the deuterium substitution (25) . Mráz et al. (27) found that, if deuterium was bound to the formyl group of N,N-dimethylformamide, N-methylformamide, or formamide, the deuterated forms eluted later than the unlabeled molecules, indicating the deuteration of the formyl group caused the molecule to be more lipophilic than the unlabeled molecule (27) . In a similar manner, deuteration of MDA, MDMA, MDEA, AMP, and MAMP near the amine would be expected to cause the deuterated drug to be more lipophilic than the non-deuterated drug. 
Quantification errors
Separation of drug and internal standard during SPE is a potential source for inaccurate quantification of drug for a sample of unknown concentration. As long as the same amount of elution solvent is used for all analytical runs, the elution disparity is not expected to cause issues, because the DI ratio will be uniformly disparate for all specimens. However, for a scenario where drug elutes before its internal standard, insufficient elution solvent used to establish a DI ratio upon calibration will lead to all subsequent quantifications being underestimated. In contrast, if less elution solvent is used for unknowns, relative to that used for the calibrator, quantities will be overestimated. The data in Table II illustrate this latter scenario, wherein insufficient volumes of the elution solvent ethyl acetate/ammonium hydroxide (98:2), were added to an SPE column containing a sample of 100 ng/mL of d-AMP and 100 ng/mL of d-MAMP relative to a calibration standard eluted with 2.0 mL of the same solvent. Figure 9 shows the relative recovery of d-MAMP and d-MAMP-d 14 as a function of elution volume. Using 1.50 mL (i.e., 0.50 mL less than was used for the calibration standard) did not affect the DI ratio, but when the elution volume was reduced to 1.00 mL, there was a 12% and 36% increase in the quantification of d-AMP and d-MAMP, respectively. This increase was due to a change in the DI ratio because of the differences in elution profiles between the drug and internal standard. These types of errors can be avoided by accurate addition of elution solvent to all of the calibrators, controls, and specimens in the analysis. Additional assurance can be achieved by using a procedure that uses sufficient excess elution solvent where small changes of elution solvent do not affect quantification or to use a procedure that has a minimal deuterium isotope effect.
Conclusions
The Deuteration of these basic drugs increased the affinity of the drug for the SPE packing material. This difference is most likely due to an increase in basicity of the amine imparted by deuteration. The difference in binding between drug and deuterated drug was greater when there was a deuterated methyl group on the amine. The relative difference in binding of drug and its deuterated analogue to DVB mixed phase SPE columns may result in quantification errors if disproportionate amounts of drug and internal standard are left on the SPE column. Adequate recovery of drug and internal standard for analysis can be achieved by applying sufficient elution solvent to assure that essentially all of the drug and internal standard are eluted from the SPE column.
Because commercial SPE columns differ in their sorbent characteristics, particle size, packing, and physical characteristics, validation procedures should evaluate elution volume and elution profiles of all analytes to assure that disproportionate losses of drug and internal standard are not occurring during the extraction process. Further study in this area with different deuterated analogues or 13 C analogues, which would not be expected to have a significant inductive effect, would be beneficial in characterizing the binding of drugs to mixed phase and other column sorbents.
